Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97: (Scientific Opinion)
Research output: Contribution to journal › Journal article › Commissioned › peer-review
Standard
Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97 : (Scientific Opinion). / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).
In: E F S A Journal, Vol. 15, No. 2, 4681, 15.02.2017.Research output: Contribution to journal › Journal article › Commissioned › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Safety of proline-specific oligopeptidase as a novel food pursuant to Regulation (EC) No 258/97
T2 - (Scientific Opinion)
AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
AU - Sjödin, Anders Mikael
N1 - EFSA 2017 4681
PY - 2017/2/15
Y1 - 2017/2/15
N2 - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase® G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase® G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use level.
AB - Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on proline-specific oligopeptidase (Tolerase® G) as a novel food ingredient submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, taking into account the comments and objections of a scientific nature raised by Member States. The novel food is an enzyme preparation of prolyl-oligopeptidase produced with a genetically modified Aspergillus niger self clone strain. The target population is the general adult population. The results from a bacterial reverse mutation test and of an in vitro chromosome aberration test did not indicate genotoxicity. The Panel considers that the reported effects observed in a 90-day rat study are treatment-related effects and can be attributed to the higher energy consumption by these animals. Taking into account the intended maximum use level for Tolerase® G, its daily consumption would correspond to 2,746 mg TOS/person or to 39.2 mg TOS/kg body weight (bw) per day, when considering a default body weight of 70 kg for an adult person. The margin between this value and the dose in the rats, which caused effects attributable to the excess energy intake, is approximately 45. Noting this margin, the Panel considers that it is unlikely that such effects would occur in human at the intended use levels. The Panel concludes that the NF, Tolerase® G, is safe for the intended use at the intended use level.
KW - Faculty of Science
KW - Novel food
KW - Proline-specific oligopeptidase
KW - Tolerase® G
KW - Ingredient
KW - Safety
U2 - 10.2903/j.efsa.2017.4681
DO - 10.2903/j.efsa.2017.4681
M3 - Journal article
VL - 15
JO - E F S A Journal
JF - E F S A Journal
SN - 1831-4732
IS - 2
M1 - 4681
ER -
ID: 188402600